Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint Company’s novel drug development program AM-411 builds on positive animal dataTreatments for rheumatoid arthritis represent the second largest therapeutic area globally AM-411 to run concurrently...

Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy Peer-reviewed study highlights high potential for cell-penetrating peptides in mRNA-based cancer treatmentsDemonstrates effective uptake and transfection capacity of Altamira’s proprietary delivery...